Marinus Q1 ZTALMY rev $7.5M (+125% YoY); cost cuts extend cash runway to Q1 2025; RAISE data summer

MARINUS PHARMACEUTICALS, INC.

2024-Q1 EPS reported -$0.68 revenue$7,679,000

ZTALMY net product revenue $7.5M vs $3.3M YoY; full-year guidance raised to $33-35M from $32-34M.
Phase 3 TrustTSC enrollment completes mid-May; topline data expected H1 Q4 2024; sNDA submission target April 2025.
Phase 3 RAISE (IV ganaxolone in RSE) enrolled 100 patients; topline results early summer 2024; RAISE II stopped.
Company reduced workforce ~20%, stopped RAISE/RAISE II enrollment, deferred IV ganaxolone manufacturing; cash $113.3M.
Net loss $38.7M ($0.68/sh) vs $34.7M ($0.67/sh) in Q1 2023; total GAAP operating expenses guided $135-140M.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MARINUS PHARMACEUTICALS, INC. reported first quarter ended March 31, 2024 results: revenue $7.5 million. Guidance raised.

Period: first quarter ended March 31, 2024
Revenue: $7.5 million
Guidance: raised
Result: reported results

Exact text from the filing

(EX-99.1) --- Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results ● ZTALMY ® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 ● Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35 million ● Enrollment to be

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-007186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.